Federal judge blocks Trump administration's changes to childhood vaccine recommendations

A federal district court judge has issued a temporary block on major changes to federal childhood vaccine recommendations that were pushed through by allies of the Trump administration's health leadership. The ruling also bars recently appointed members of the key federal vaccine advisory panel from serving in their roles while the legal challenge proceeds. Both measures will remain in place until the court hears further arguments on the merits of the case.

The case targets changes made to the Advisory Committee on Immunization Practices, known as ACIP, which is the CDC's expert panel responsible for recommending which vaccines should be included in the standard childhood immunization schedule. ACIP recommendations carry significant practical weight: they are the basis for state school vaccination requirements, insurance coverage mandates under the Affordable Care Act, and Vaccines for Children program eligibility, which provides free vaccines to roughly half of all children in the United States.

What the Trump administration changed and how it did it

The changes at ACIP began after HHS Secretary Robert F. Kennedy Jr. moved to replace the committee's established scientific membership with new appointees who share his longstanding scepticism of the existing vaccine schedule. Kennedy has questioned the safety of multiple childhood vaccines for years, including MMR, the combined measles, mumps, and rubella vaccine, and had previously called for a re-evaluation of the childhood immunization schedule on the basis of what he described as insufficient safety data.

The newly appointed ACIP members then voted to remove several vaccines, including the COVID-19 vaccine and the hepatitis B birth dose, from the recommended childhood schedule. Removing a vaccine from ACIP's recommended schedule has immediate consequences. Insurers are no longer required to cover it without cost-sharing. State school entry requirements that reference the federal schedule may no longer apply. Paediatricians lose a clear clinical reference point that most use directly in their practice.

The legal argument behind the injunction

The lawsuit was filed by a coalition that includes the American Academy of Paediatrics, the Infectious Diseases Society of America, and several state health departments. The legal challenge rests on two main arguments. First, that the ACIP appointments violated the Federal Advisory Committee Act, which requires that advisory committee members be selected for their scientific expertise and not for their alignment with political objectives. Second, that the process used to remove vaccines from the schedule bypassed the notice-and-comment rulemaking requirements of the Administrative Procedure Act.

The district court judge, ruling in the District of Columbia, found that the plaintiffs had demonstrated a substantial likelihood of success on the merits, which is the standard required to issue a preliminary injunction. The judge also found that the potential harm from allowing the schedule changes to take effect during litigation, including decreased vaccination rates and increased exposure to preventable disease, outweighed any administrative disruption from blocking the changes temporarily.

What the hepatitis B birth dose removal would have meant in practice

The hepatitis B birth dose is given to newborns within 24 hours of birth and has been on the recommended schedule since 1991. It prevents vertical transmission of hepatitis B from mothers who are infected but whose status is not known at delivery. Approximately 1,000 infants per year in the United States are born to mothers with undetected hepatitis B, according to CDC data. Without the birth dose, a significant fraction of those infants would develop chronic hepatitis B infection, which carries long-term risks including cirrhosis and liver cancer.

The ACIP vote to remove the birth dose had already prompted three major hospital systems to announce they would continue administering it regardless of the federal recommendation change, citing their own clinical protocols. The court ruling effectively makes that institutional response unnecessary for the time being, but the episode illustrated how quickly the practical effects of a schedule change can propagate through clinical settings before any legal challenge is resolved.

The COVID-19 vaccine removal and insurance coverage implications

Removing the COVID-19 vaccine for children from the ACIP schedule would have ended the requirement for private insurers to cover it without cost-sharing under the Affordable Care Act's preventive services mandate. The ACA requires no-cost coverage for any vaccine that receives an ACIP recommendation. Once removed from the schedule, the vaccine would revert to the same coverage status as non-recommended medical services, meaning families could face out-of-pocket costs depending on their insurer and plan.

The Vaccines for Children program, which provides federally purchased vaccines at no cost to children on Medicaid, uninsured children, and children in certain underserved settings, is also tied to ACIP recommendations. Removal from the schedule would have ended VFC eligibility for the COVID-19 vaccine, affecting an estimated 40 million children who receive their vaccines through VFC providers.

What happens next in the litigation

The Department of Justice is expected to appeal the preliminary injunction to the US Court of Appeals for the DC Circuit. A hearing on the full merits of the case is scheduled for June 2026. If the appellate court declines to stay the injunction pending appeal, the schedule changes and the new ACIP appointments will remain blocked until the merits hearing concludes. The litigation will also examine whether HHS exceeded its statutory authority in restructuring ACIP's membership and whether the committee's new composition violates the Federal Advisory Committee Act's balance-of-viewpoints requirement.